

GLAXOSMITHKLINE PLC  
Form 6-K  
August 04, 2010

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending August 2010

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

Financial Services Authority

GlaxoSmithKline plc received on 4 August 2010 from Legal & General Group plc a notification of interests in GlaxoSmithKline plc Ordinary shares of 25 pence each, dated on 4 August 2010. This notice is given in accordance with DTR 5.8.12.

Financial Services Authority

**TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES**

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached: **GlaxoSmithKline plc**

2. Reason for the notification (please tick the appropriate box or boxes):  
An acquisition or disposal of voting rights **Yes**

An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached.

An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation: Legal & General Group Plc (L&G)

4. Full name of shareholder(s) (if different from 3.): Legal & General Assurance (Pensions Management) Limited (PMC)

5. Date of the transaction and date on which the threshold is crossed or reached: 03 August 2010

6. Date on which issuer notified: 04 August 2010

7. Threshold(s) that is/are crossed or reached: From 3% to 4%

**8. Notified details:**

A: Voting rights attached to shares

| Class/type of shares<br>if possible using the ISIN CODE | Situation previous to the triggering transaction |                         | Resulting situation after the triggering transaction |                         |                    |
|---|--|-------------------------|--|-------------------------|--------------------|
|   | Number of Shares                                 | Number of Voting Rights | Number of shares                                     | Number of voting rights | % of voting rights |
| Ordinary 25p  | 207,179,146                                      | 146                     | 208,149,243  | 243                     | 4.00%              |
|   | (As on 02/08/2010)                               |                         |  |                         |                    |

**B: Qualifying Financial Instruments**

Resulting situation after the triggering transaction

| Type of financial instrument | Expiration date | Exercise/ Conversion Period | Number of voting rights that may be acquired if | % of voting rights |
|------------------------------|-----------------|-----------------------------|---|--------------------|
|------------------------------|-----------------|-----------------------------|---|--------------------|

**the  
instrument  
is  
exercised/  
converted.**

**C: Financial Instruments with similar economic effect to Qualifying  
Financial Instruments  
Resulting situation after the triggering transaction**

| <b>T y p e o f<br/>financial<br/>instrument</b> | <b>Exercise<br/>price</b> | <b>Expiration<br/>date</b> | <b>Exercise/<br/>C o n v e r s i o n<br/>period</b> | <b>Number of<br/>v o t i n g<br/>r i g h t<br/>instrument<br/>refers to</b> | <b>% o f<br/>v o t i n g<br/>r i g h t s</b> |
|---|---------------------------|----------------------------|---|---|--|
|---|---------------------------|----------------------------|---|---|--|

**Nominal Delta**

**Total (A+B+C)**

**Number of voting rights**

208,149,243

**Percentage of  
voting rights**

4.00%

**9. Chain of controlled undertakings through which the voting rights  
and/or the  
financial instruments are effectively held, if applicable:**

Legal & General Group Plc (Direct and  
Indirect) (Group)

Legal & General Investment Management  
(Holdings) Limited (LGIMH) (Direct and  
Indirect)

Legal & General Investment Management  
Limited (Indirect) (LGIM)

Legal & General Group Plc (Direct) (L&G)  
(208,149,243 - 4.00%= LGAS, LGPL & PMC)

Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD) (174,450,467 - 3.35% = PMC)

Legal & General Insurance Holdings  
Limited (Direct) (LGIH)

Legal & General Assurance (Pensions  
Management) Limited (PMC)  
(174,450,467 - 3.35% = PMC)

Legal & General Assurance Society  
Limited (LGAS & LGPL)

Legal & General Pensions Limited  
(Direct) (LGPL)

**Proxy Voting:**

**10. Name of the proxy holder:** N/A

**11. Number of voting rights proxy holder will cease to hold:** N/A

**12. Date on which proxy holder will cease to hold voting rights:** N/A

**13. Additional information:** Notification using the total voting rights figure of 5,192,669,600

**14. Contact name:** Paul Toon (LGIM)

**15. Contact telephone number:** 020 3124 3854

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: August 04, 2010

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc